EGFR单抗联合CIK细胞治疗胃癌的实验研究

Experimental Study of EGFR Monoclonal Antibody Combined with CIK Cells for the Treatment of Gastric Cancer

单克隆抗体靶向药物和细胞免疫治疗在恶性肿瘤的治疗中越来越显现出巨大的潜力，但二者联合应用在胃癌治疗中的作用尚未明确。目的：通过体外和体内实验初步探讨表皮生长因子受体（EGFR）单抗（西妥昔单抗）联合细胞因子诱导的杀伤细胞（CIK细胞）对胃癌的治疗作用。方法：经免疫细胞化学方法证实人胃腺癌细胞株SGC7901高表达EGFR后．观察EGFR单抗对CIK细胞与SGC7901细胞结合率的影响。设置EGFR单抗联合CIK细胞组、单纯CIK细胞组和单纯EGFR单抗组，以MTT法检测各组对SGC7901细胞的杀伤率．应用裸鼠移植瘤模型观察各组抑瘤率。结果：EGFR单抗未能显著提高CIK细胞与SGC7901细胞的结合率。EGFR单抗联合CIK细胞对SGC7901细胞的杀伤率和裸鼠移植瘤抑制率显著高于两者单用（P〈0．05）。结论：EGFR单抗与CIK细胞联合对胃癌的疗效较两者单用显著提高．

Background： Monoclonal antibody targeted drugs and cellular immunotherapy have shown great potential in the treatment of malignant tumors, but the therapeutic effect of their combined use on gastric cancer is still unclear. Aims： To investigate the therapeutic effect of epidermal growth factor receptor （EGFR） monoclonal antibody （cetuximab） combined with cytokine-induced killer cells （CIK cells） on gastric cancer by in vitro and in vivo experiments. Methods： The over-expression of EGFR in human gastric adenocarcinoma cell line SGC7901 was confirmed by immunocytochemistry assay, and the effect of EGFR monoclonal antibody on the binding between CIK cells and SGC7901 cells was investigated. The experiment was divided into three groups： EGFR monoelonal antibody combined with CIK ceils group, CIK cells group and EGFR monoclonal antibody group. MTT assay was used to measure the killing rate against SGC7901 cells in each group, and the tumor inhibition rate was assessed by the xenograft growth in nude mice. Results： EGFR monoclonal antibody did not significantly improve the binding rate of CIK cells with SGC7901 cells. Compared with CIK cells group and EGFR monoclonal antibody group, both the killing rate and the tumor inhibition rate were significantly higher in EGFR monoclonal antibody combined with CIK cells group （P〈0.05）. Conclusions： EGFR monoclonal antibody combined with CIK cells demonstrates greater therapeutic effect on gastric cancer when compared with their single use.